Based on this YouTube video's total view count of 193 views and industry-standard rates, the estimated total earning is $0 - $0 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore EHA 2025 | Latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL with 193 views, 0 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the STARGLO trial of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) vs rituximab plus gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). In this interview, Gregory shares data from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL. Gregory covers key outcomes, highlighting 2-year efficacy and safety data. He concludes that the data are encouraging and support using this combination as a fixed-duration, off-the-shelf therapy for patients with R/R DLBCL. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.